Q
Quinlan L. Sievers
Researcher at Broad Institute
Publications - 23
Citations - 2830
Quinlan L. Sievers is an academic researcher from Broad Institute. The author has contributed to research in topics: Ubiquitin ligase & Chronic lymphocytic leukemia. The author has an hindex of 10, co-authored 20 publications receiving 2368 citations. Previous affiliations of Quinlan L. Sievers include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang,Michael S. Lawrence,Youzhong Wan,Petar Stojanov,Carrie Sougnez,Kristen E. Stevenson,Lillian Werner,Andrey Sivachenko,David S. DeLuca,Li Zhang,Wandi Zhang,Alexander R. Vartanov,Stacey M. Fernandes,Natalie R. Goldstein,Eric G. Folco,Kristian Cibulskis,Bethany Tesar,Quinlan L. Sievers,Erica Shefler,Stacey Gabriel,Nir Hacohen,Robin Reed,Matthew Meyerson,Todd R. Golub,Eric S. Lander,Donna Neuberg,Jennifer R. Brown,Gad Getz,Catherine J. Wu +28 more
TL;DR: This study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocrytic leukemia.
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang,Michael S. Lawrence,Youzhong Wan,Petar Stojanov,Carrie Sougnez,Kristen E. Stevenson,Lillian Werner,Andrey Sivachenko,David S. DeLuca,Li Zhang,Wandi Zhang,Alexander R. Vartanov,Stacey M. Fernandes,Natalie R. Goldstein,Eric G. Folco,Kristian Cibulskis,Bethany Tesar,Quinlan L. Sievers,Erica Shefler,Stacey Gabriel,Nir Hacohen,Robin Reed,Matthew Meyerson,Todd R. Golub,Eric S. Lander,Donna Neuberg,Jennifer R. Brown,Gad Getz,Catherine J. Wu +28 more
TL;DR: In this article, the authors proposed a method to detect the presence of cancer in the human genome using the Human Genome Research Institute (HGRI) grant U54HG003067.
Journal ArticleDOI
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Quinlan L. Sievers,Quinlan L. Sievers,Georg Petzold,Richard D. Bunker,Aline Renneville,Aline Renneville,Mikolaj Slabicki,Mikolaj Slabicki,Mikolaj Slabicki,Brian J. Liddicoat,Brian J. Liddicoat,Wassim Abdulrahman,Tarjei S. Mikkelsen,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert,Nicolas H. Thomä +16 more
TL;DR: The human ZF “degrome” is defined in the context of thalidomide, lenalidomid, and pomalidomides to characterize the ZF-drug-CRBN interaction structurally and functionally and determine whether different thalidmide analogs degrade distinct ZFs.
Journal ArticleDOI
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Mikolaj Slabicki,Mikolaj Slabicki,Mikolaj Slabicki,Zuzanna Kozicka,Zuzanna Kozicka,Georg Petzold,Yen-Der Li,Yen-Der Li,Manisha Manojkumar,Manisha Manojkumar,Manisha Manojkumar,Richard D. Bunker,Katherine A. Donovan,Quinlan L. Sievers,Quinlan L. Sievers,Jonas Koeppel,Jonas Koeppel,Jonas Koeppel,Dakota Suchyta,Dakota Suchyta,Adam S. Sperling,Adam S. Sperling,Emma C. Fink,Emma C. Fink,Jessica A. Gasser,Jessica A. Gasser,Li R. Wang,Steven M. Corsello,Steven M. Corsello,Rob S. Sellar,Rob S. Sellar,Rob S. Sellar,Max Jan,Max Jan,Dennis Gillingham,Claudia Scholl,Stefan Fröhling,Todd R. Golub,Todd R. Golub,Todd R. Golub,Eric S. Fischer,Nicolas H. Thomä,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +44 more
TL;DR: It is demonstrated that chemical alteration of surface-exposed moieties can confer gain-of-function glue properties to an inhibitor, and this is proposed as a broader strategy through which target-binding molecules could be converted into molecular glues.
Journal ArticleDOI
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan,Max Jan,Irene Scarfò,Rebecca C. Larson,Amanda Walker,Amanda Walker,Amanda Walker,Andrea Schmidts,Andrew A Guirguis,Andrew A Guirguis,Jessica A. Gasser,Jessica A. Gasser,Mikolaj Slabicki,Mikolaj Slabicki,Amanda A. Bouffard,Ana P. Castano,Michael Kann,Maria L. Cabral,Alexander Tepper,Alexander Tepper,Daniel E Grinshpun,Daniel E Grinshpun,Adam S. Sperling,Adam S. Sperling,Taeyoon Kyung,Quinlan L. Sievers,Michael E. Birnbaum,Marcela V. Maus,Marcela V. Maus,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert +31 more
TL;DR: In this article, the authors developed ON and OFF switches for CAR T cells using the clinically approved drug lenalidomide, which mediates the proteasomal degradation of several target proteins by inducing interactions between the CRL4CRBN E3 ubiquitin ligase and a C2H2 zinc finger degron motif.